Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients

Consuelo M López De Padilla¹, Molly S Hein¹, Cynthia S Crowson¹,², Christopher S Choo¹, Abigail B Green², Michelle Petri⁴, Hatice Bilgic⁵, Emily C Baechler⁵, and Ann M Reed¹,³

Abstract

Objective: We investigated ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif, member 13) messenger RNA levels as a biomarker of disease features in systemic lupus erythematosus.

Methods: We measured and compared messenger RNA (mRNA) levels of ADAMTS13 in peripheral blood cells in patients with systemic lupus erythematosus and healthy control subjects by whole-genome microarray. We retrospectively analyzed the correlations of ADAMTS13 mRNA expression with clinical features, laboratory parameters, therapeutic features, and disease activity (according to the Systemic Lupus Erythematosus Disease Activity Index). We also examined the association of three single nucleotide polymorphisms (rs4962145, rs2285467, and rs685523) of the ADAMTS13 gene with patient characteristics.

Results: In 309 patients, the median ADAMTS13 mRNA expression levels were significantly higher in blood cells of systemic lupus erythematosus patients than in 23 healthy controls (p = .03). Notably, ADAMTS13 mRNA expression levels were significantly higher in systemic lupus erythematosus patients with a history of stroke (p = .02) or transient ischemic attack (p = .02). Among the three single nucleotide polymorphisms analyzed, rs2285467 was significantly associated with stroke (p = .03) and anticardiolipin antibodies (p = .04).

Conclusions: Increased expression of ADAMTS13 mRNA in blood cells is associated with the presence of ischemic cerebrovascular disease in systemic lupus erythematosus patients and suggests a potential role for ADAMTS13 in the pathogenesis of ischemic cerebrovascular disease in these patients.

Keywords
ADAMTS13, atherosclerosis, cardiovascular disease, gene polymorphism, systemic lupus erythematosus

Date received: 26 August 2013; accepted: 25 October 2013

Introduction

ADAMTS13 protease, a disintegrin-like and metalloprotease with thrombospondin type 1 motif, member 13, is known to cleave highly active, thrombogenic, ultralarge von Willebrand factor (vWF) multimers into less active, small-molecular-weight multimers, thereby controlling vWF-mediated platelet thrombus formation. ADAMTS13, also known as the vWF-cleaving protease, belongs to a recently described group of secreted metalloproteinase enzymes, the ADAM and matrix metalloproteinase families of proteases (ADAMTS). Emerging evidence suggests that members of the ADAMTS protease family play important roles in disorders such as arthritis (ADAMTS4 and ADAMTS5), arterial thrombosis (ADAMTS13), and cancer (ADAMTS1). Recent studies have just begun to establish roles for the ADAMTS proteases in atherosclerosis and inflammation (ADAMTS1, ADAMTS4, ADAMTS5, and ADAMTS8)."
However, the biological function of most ADAMTS proteases is not yet well known.

Importantly, a deficiency of ADAMTS13 is associated with thrombotic thrombocytopenic purpura (TTP), a potentially lethal syndrome that often occurs concurrently with systemic lupus erythematosus (SLE). SLE is a chronic multisystem autoimmune disease with a broad range of clinical manifestations, including photosensitive rashes, discoid lesions, arthritis and arthralgia, renal disorders, cardiac and pulmonary disease, and central nervous system disorders. SLE has in common with TTP several pathogenic triggers and clinical findings (fever, central nervous system involvement, renal impairment, hemolytic anemia, and thrombotic events), although they are distinct entities. While the pathogenic role of ADAMTS13 in TTP associated with SLE has been well investigated, information on ADAMTS13 and other clinical manifestations of SLE is limited.

On the basis of this background, we examined whether expression levels of ADAMTS13 mRNA (messeger RNA) in peripheral blood cells vary among different clinical, immunologic, and laboratory features in SLE patients, and whether ADAMTS13 mRNA expression levels depend on disease activity. We subsequently investigated whether ADAMTS polymorphisms predispose to any particular manifestation of SLE. We found that ADAMTS13 mRNA expression levels in blood cells are associated with the presence of ischemic cerebrovascular disease (stroke or transient ischemic attack (TIA)) in SLE patients without evidence of TTP and suggests a potential role for ADAMTS13 in the pathogenesis of ischemic cerebrovascular disease in SLE patients.

Patients and methods

Patients and clinical assessment

This study was carried out in accordance with research protocols approved by institutional review boards of Mayo Clinic, Rochester, Minnesota; University of Minnesota School of Medicine, Minneapolis, Minnesota; and Johns Hopkins University School of Medicine, Baltimore, Maryland. Informed consent was provided by all study participants. Peripheral blood samples were obtained from patients who fulfilled at least four criteria of the American College of Rheumatology for SLE and healthy controls. Patients included in this study were enrolled from the Hopkins Lupus Cohort under the auspices of the Autoimmunity Biomarkers Collaborative Network. Data were collected retrospectively for all patients regarding the presence or absence of each individual American College of Rheumatology criterion for SLE signs and symptoms associated with organ-system involvement; presence or absence of SLE-associated autoantibodies, including antinuclear antibody, anti-Ro, anti-La, anti-Sm, anti-RNP, anti-dsDNA, antiphospholipid, and anti-cardiolipin antibodies; clinical laboratory tests; medication profile; and the SLE Disease Activity Index (SLEDAI).

Subsequently, history of major cardiovascular risk factors (smoking, diabetes, and hypertension) was obtained from all SLE patients. Samples were collected and studied from an array of patients ranging from those with newly diagnosed disease to those with a longstanding diagnosis. Data were collected using the REDCap system.

ADAMTS13 gene expression

Total RNA was isolated from whole blood collected in tubes treated with an RNA stabilization agent (PAXgene; PreAnalytix, Hombrechstit, Switzerland) and stored at −80°C until RNA isolation. RNA was isolated using an RNA-purification kit (PAXgene Blood RNA kit) following the manufacturer’s instructions and subjected to an on-column DNase I treatment. Labeled complementary RNA was generated from total RNA using the manufacturer’s protocol (Illumina TotalPrep RNA Amplification Kit; Life Technologies, Grand Island, NY) using manufacturer’s protocol. The labeled complementary RNA was hybridized to expression arrays (Illumina Human WG-6v2 BeadChip; Illumina, San Diego, CA). Data quality assessment and quantile normalization were performed (Illumina Genome Studio software). To reduce noise contributed by genes expressed at very low levels, expression values that had a detection p value higher than .1 were replaced with the minimum detectable expression value for that gene (p < .1).

Genotyping

Three polymorphisms from ADAMTS13 (rs4962145, rs2285467, and rs685523) were genotyped (Illumina Human Hap550v3 Genotyping BeadChip) at the Feinstein Institute for Medical Research, Manhasset, New York. These data were generated as part of a genomewide association study to identify risk loci associated with SLE.

Statistical analysis

Descriptive statistics (means, medians, ranges, percentages, etc.) were used to summarize the data. The χ² test was used for discrete variables, and the Kruskal–Wallis test was used to compare continuous variables between groups (e.g. with and without SLE, with and without certain patient characteristics, and genotypes). Spearman rank correlation methods were used to examine potential associations between ADAMTS13 levels and continuous characteristics (e.g. SLEDAI).

Results

Patient clinical features and their correlation with ADAMTS13 mRNA expression

The study included 309 subjects with SLE (280 women, 29 men), with a mean ± SD age of 44.1 ± 12.5 years. All patients in the study were White. The mean ± SD disease duration was 13.8 ± 9.6 years. The range of SLEDAI scores was from
Table 1. Patient characteristics (N = 309).

| Characteristic                  | Valuea |
|--------------------------------|--------|
| Female sex                     | 280 (91) |
| Age, mean ± SD (years)         | 44.1 ± 12.5 |
| White race                     | 309 (100) |
| SLE duration, mean ± SD (years)| 13.8 ± 9.6 |
| SLEDAI, mean ± SD (range)      | 1.8 ± 2.7 (0–14) |
| Skin involvementb               | 241 (78) |
| Arthritisb                     | 224 (72) |
| Serositisb                     | 149 (48) |
| Renal disordersb               | 183 (59) |
| Neurologic disorders (seizures or psychosis)b| 4 (1) |
| Hemolytic anemiab              | 28 (9) |
| Leukopeniab                    | 184 (60) |
| Thrombocytopeniab              | 66 (21) |
| Anti-dsDNA positiveb           | 163 (53) |
| Anti-Sm positiveb              | 25 (8) |
| Antiphospholipidb              | 182 (59) |
| Antinuclear antibodiesb        | 293 (95) |
| Lupus anticoagulant            | 95 (31) |
| Anti-RNP                       | 32 (11) |
| Cardiovascular risk factors    |        |
| Smoking (former or current)    | 115 (37) |
| Hypertension                   | 125 (41) |
| Diabetes                       | 24 (8) |
| Medications                    |        |
| Any DMARD (current use at study visit) | 219 (71) |
| Plaquenil                      | 203 (66) |
| Cyclophosphamide               | 16 (5) |
| Methotrexate                   | 14 (5) |
| Chloroquine                    | 6 (2) |
| Dapsone                        | 11 (4) |
| Prednisone                     | 136 (55) |

DMARD: disease-modifying antirheumatic drug; SLE: systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; anti-RNP: anti-ribonucleoprotein.

aValues are number (percentage) unless indicated otherwise.

bThe American College of Rheumatology revised classification criteria for SLE, adapted from Hochberg.17

Figure 1. Comparison of ADAMTS13 gene expression for 23 healthy control subjects and 309 patients with SLE.
SLE: systemic lupus erythematosus; ADAMTS13: a disintegrin-like and metalloprotease with thrombospondin type 1 motif, member 13.
The y-axis represents ADAMTS13 gene expression. The horizontal bars indicate medians. ADAMTS13 mRNA expression levels were significantly higher in SLE patients (median, 121.3 (25th, 75th quartile, 116.8, 126.4)) than in healthy controls (median, 119.1 (25th, 75th quartile, 114.8, 121.3)).

More disease-modifying antirheumatic drugs, such as anti-malarials, methotrexate, cyclophosphamide, and dapsone, either alone or in combination with corticosteroids at the time of the blood draw. A total of 250 patients had a history of previous corticosteroid treatment.

Correlation of ADAMTS13 mRNA expression with clinical features in SLE patients

The results of measuring and comparing ADAMTS13 mRNA levels in peripheral blood cells showed that the median ADAMTS13 mRNA expression levels were significantly higher in the 309 SLE patients (median, 121.3 (25th, 75th quartile, 116.8, 126.4)) than in the 23 healthy controls (median, 119.1 (25th, 75th quartile, 114.8, 121.3)) (p = .03) (Figure 1).

Table 2 classifies SLE patients according to the presence or absence of clinical features of SLE. No significant differences were found between ADAMTS13 mRNA expression levels and skin manifestations, arthritis, serositis
Table 2. ADAMTS13 gene expression by clinical features.a

| Clinical feature                  | Patients without characteristic | Patients with characteristic | p value |
|----------------------------------|---------------------------------|-----------------------------|---------|
| No.                              | ADAMTS13 level                  | No.                         | ADAMTS13 level |
| Thrombocytopenia                 | 243 121.3 (116.8, 126.4)         | 66 121.4 (115.7, 126.4)     | .85     |
| Hemolytic anemia                 | 281 121.2 (116.7, 126.3)         | 28 123.2 (116.2, 128.0)     | .55     |
| Proteinuria                      | 209 120.8 (116.2, 126.3)         | 100 122.3 (117.4, 126.4)    | .27     |
| Hematuria                        | 232 120.8 (115.8, 126.3)         | 77 122.4 (118.4, 127.7)     | .12     |
| Thrombotic                       | 304 121.3 (116.8, 126.4)         | 5 115.2 (115.1, 118.1)      | .17     |
| thrombocytopenic purpura         |                                 |                             |         |
| Stroke                           | 298 121.0 (116.6, 126.3)         | 11 126.5 (121.3, 129.2)     | .02     |
| Transient ischemic attack        | 154 121.6 (116.6, 127.4)         | 5 126.6 (126.3, 137.8)      | .02     |
| Myocardial infarction            | 301 121.3 (116.8, 126.4)         | 8 123.1 (117.2, 125.2)      | .82     |
| Increased liver function tests   | 196 120.9 (115.8, 126.2)         | 113 121.6 (117.5, 127.2)    | .13     |
| Smoking (former or current)      | 194 121.4 (117.2, 126.1)         | 115 121.1 (116.8, 126.0)    | .86     |
| Hypertension                     | 184 121.3 (116.5, 126.4)         | 125 121.3 (116.9, 126.4)    | .70     |
| Diabetes                         | 285 121.2 (116.8, 126.2)         | 24 124.7 (116.7, 129.5)     | .18     |
| DVT                              | 268 120.9 (116.5, 126.2)         | 41 125.0 (118.4, 128.5)     | .057    |

aValues in the table are median (25th, 75th quantile). Bold type indicates a statistically significant result.

(pleuritis or pericarditis), renal disorder (hematuria, persistent proteinuria, or cellular casts), neurologic disorder (seizures or psychosis), hematologic disorder (hemolytic anemia, leukopenia, or lymphopenia), and thrombocytopenia. In addition, no significant differences were found between ADAMTS13 mRNA expression levels and TTP manifestations (p = .17). We found that ADAMTS13 mRNA expression in blood cells did not correlate with disease activity (SLEDAI) (p = .71). Notably, ADAMTS13 mRNA expression levels were significantly higher in SLE patients with a history of ischemic stroke (p = .02) or TIA (p = .02) than in those without stroke or TIA.

No significant differences were observed between ADAMTS13 mRNA levels in the 26 SLE patients with coronary artery disease compared with those without coronary artery disease (p = .35). No association was found between ADAMTS13 mRNA levels and presence of cardiovascular risk factors (smoking, hypertension, and diabetes).

Plasma ADAMTS13 activity has been found to correlate with serum aspartate aminotransferase and alanine aminotransferase in patients with liver diseases,22 suggesting that plasma ADAMTS13 activity may reflect hepatocellular damage. We found no significant differences between ADAMTS13 mRNA in SLE patients with elevated liver function test results compared with SLE patients with normal liver function (p = .13).

Patient clinical features and ADAMTS13 polymorphisms

In a subgroup of 261 patients enrolled in this study, polymorphism rs2285467 was significantly associated with stroke (p = .03) (Table 3) and anticardiolipin antibodies (p = .04) (data not shown), and rs685523 was associated with hemolytic anemia (p = .03) (Table 3). No other SLE clinical features were differentially represented in the genotype distribution of each ADAMTS13 polymorphism.

Discussion

In this study, we demonstrated by whole-genome microarray that ADAMTS13 mRNA expression levels were higher in SLE patients than in healthy controls. ADAMTS13 mRNA expression levels significantly correlated with the presence of ischemic stroke or TIA. It is well recognized that patients with SLE are at a five- to six-fold increased risk of myocardial infarction and stroke compared with the general population.23–25 The pathogenic mechanisms underlying this increased risk of cardiovascular disease are not fully understood. It is increasingly accepted that accelerated atherosclerotic disease appears to be a major underlying mechanism of cardiovascular disease among SLE patients and in patients with other autoimmune diseases.26,27 Whether this accelerated atherosclerosis and premature cardiovascular disease arise through the same or different mechanisms from those in the general population without SLE remains unclear. The risk of cardiovascular disease in SLE patients seems to be independent of traditional cardiovascular risk factors.28 To our knowledge, decreased plasma ADAMTS13 activity (usually <5% of normal), which results in accumulation of prothrombotic, ultralarge vWF multimers in the blood circulation, has been the main pathophysiologic mechanism by which ADAMTS13 is linked to the development of thrombotic diseases. In a recent study, decreased plasma ADAMTS13 activity was implicated as a risk factor for pediatric stroke.29 Our data were analyzed retrospectively; therefore, we could not determine the ADAMTS13 and vWF activity in plasma. However, we did not anticipate a
A deficiency of ADAMTS13 activity in our SLE patients with ischemic cerebral events since our results showed an upregulation of ADAMTS13 mRNA, which could result in normal or increased plasma ADAMTS13 concentration.

Atherosclerotic plaque disruption with subsequent thrombus formation is a key event that leads to atherothrombosis. Recent studies showed that ADAMTS13 could modulate thrombus formation in atherosclerotic coronary arteries, where it was found colocalized with platelet-rich thrombi. ADAMTS13 shares homology and domain structures with members of ADAMTS proteases. ADAMTS proteases are a multidomain, secreted, extracellular zinc metalloproteinase family with 19 members in humans. These proteases are known to cleave a wide range of proteins in the extracellular matrix. In recent years, there has been growing evidence concerning the role of several members of ADAMTS proteases in the pathogenesis of atherothrombosis. These proteases act by breaking down key proteoglycans of the arterial walls such as versican and brevican. For instance, Wågsäter et al. have demonstrated that levels of ADAMTS4 and ADAMTS8 mRNAs are at a three-fold increase in macrophage-rich areas of atherosclerotic lesions, and their expressions can be upregulated by the proinflammatory cytokines interferon γ and tumor necrosis factor α. Moreover, a recent report also demonstrated an association of four ADAMTS genes (ADAMTS2, ADAMTS12, ADAMTS13, and ADAMTS17) in conjunction with extracellular matrix components with susceptibility for pediatric stroke. In our study, we found that ADAMTS13 polymorphism rs2285467 was significantly associated with stroke.

To our knowledge, this is the first study to associate ADAMTS13 mRNA expression in peripheral blood cells with ischemic stroke in SLE patients and suggests a potential role for the ADAMTS13 gene in ischemic cerebrovascular disease in SLE patients. Nevertheless, it remains to be determined whether the upregulation of ADAMTS13 is beneficial or detrimental to the process of cerebral atherothrombosis and whether ADAMTS13 has a role in the process of regeneration of brain function after focal brain ischemia. Therefore, further studies are required to better understand the physiologic and pathologic function of this protease in ischemic cerebrovascular injury. As this function becomes more clearly defined, new therapeutic targets may emerge.

Table 3. Association between ADAMTS13 gene polymorphisms and selected clinical characteristics (n = 261).a

| Characteristics | Polymorphismb | Thrombocytopenia | Hemolytic anemia | Proteinuria | Hematuria | TTP | Stroke | TIA | MI | Hypertension |
|-----------------|--------------|-----------------|-----------------|------------|----------|-----|-------|-----|----|-------------|
| rs4962145       |              |                 |                 |            |          |     |       |     |    |             |
| AA (n = 257)    | 60 (23)      | 25 (10)         | 84 (33)         | 192 (75)   | 4 (2)    | 7 (3)| 5 (4) | 7 (3) | 104 (40) |
| GA (n = 24)     | 3 (13)       | 2 (8)           | 11 (46)         | 18 (75)    | 1 (4)    | 1 (4)| 0 (0) | 0 (0) | 9 (38)   |
| GG (n = 5)      | 2 (40)       | 1 (20)          | 3 (60)          | 2 (40)     | 0 (0)    | 1 (20)| 0 (0) | 0 (0) | 1 (20)   |
| p value         | .31          | .72             | .20             | .21        | .62      | .09 | .81   | .67  | .63 |
| rs2285467c      |              |                 |                 |            |          |     |       |     |    |             |
| AA (n = 256)    | 60 (23)      | 25 (10)         | 84 (33)         | 65 (25)    | 4 (2)    | 7 (3)| 5 (4) | 7 (3) | 105 (41) |
| GA (n = 5)      | 2 (40)       | 1 (20)          | 3 (60)          | 3 (60)     | 0 (0)    | 1 (20)| 0 (0) | 0 (0) | 2 (40)   |
| p value         | .39          | .45             | .20             | .08        | .78      | .03 | .73   | .71  | .96 |
| rs685523        |              |                 |                 |            |          |     |       |     |    |             |
| AA (n = 3)      | 0 (0)        | 0 (0)           | 2 (67)          | 2 (67)     | 0 (0)    | 0 (0)| 0 (0) | 0 (0) | 2 (67)   |
| AG (n = 54)     | 8 (15)       | 10 (19)         | 21 (39)         | 11 (20)    | 2 (4)    | 3 (6)| 1 (3) | 1 (2) | 23 (43)  |
| GG (n = 246)    | 58 (24)      | 18 (7)          | 76 (31)         | 62 (25)    | 3 (1)    | 8 (3)| 4 (3) | 7 (3) | 97 (39)  |
| p value         | .24          | .03             | .24             | .18        | .42      | .68 | .96   | .88  | .59 |

ADAMTS13, a disintegrin-like and metalloprotease with thrombospondin type 1 motif, member 13; MI, myocardial infarction; TIA, transient ischemic attack; TTP, thrombotic thrombocytopenic purpura.

aValues are number (percentage) unless indicated otherwise. Statistically significant results are shown in bold.

bThe number in parentheses indicates the number of patients positive for AA, GA, and GG in the genotypic distribution of each polymorphism.

cNo patient had the GG genotype for rs2285467.
1. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. 
*J Biol Chem* 2001; 276: 41059–41063.

2. Porter S, Clark IM, Kevorkian L, et al. The ADAMTS metalloproteinases. *Biochem J* 2005; 386: 15–27.

3. Tortorella MD, Malfait F, Barve RA, et al. A review of the ADAMTS family, pharmaceutical targets of the future. *Curr Pharm Des* 2009; 15: 2359–2374.

4. Song RH, Tortorella MD, Malfait AM, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. *Arthritis Rheum* 2007; 56: 575–585.

5. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature* 2001; 413: 488–494.

6. Rocks N, Paulissen G, Quesada-Calvo F, et al. ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. *Cancer Res* 2008; 68: 9541–9550.

7. Jonsson-Rylander AC, Nilsson T, Fritsche-Danielson R, et al. Unusually large plasma rich areas of human atherosclerotic plaques. *Atherosclerosis* 2008; 196: 514–522.

8. Kenagy RD, Min SK, Clowes AW, et al. Cell death-associated ADAMTS4 and versican degradation in vascular tissue. *J Histochim Cytochem* 2009; 57: 889–897.

9. Didangelos A, Mayr U, Monaco C, et al. Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis. *J Biol Chem* 2012; 287: 19341–19345.

10. Wägsäuer D, Bjork H, Zhu C, et al. ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. *Atherosclerosis* 2008; 196: 514–522.

11. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. *N Engl J Med* 1982; 307: 1432–1435.

12. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. *Blood* 1997; 89: 3097–3103.

13. Tsai HM and Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. *N Engl J Med* 1998; 339(22): 1585–1594.

14. Majithia V and Harisdangkul V. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a frequent and severe consequence of active disease. *Rheumatology (Oxford)* 2006; 45: 1170–1171.

15. George JN, Vesely SK and James JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. *South Med J* 2007; 100: 512–514.

16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982; 25: 1271–1277.

17. Hoehberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; 40: 1725.

18. Petri M. Hopkins Lupus Cohort. 1999 update. *Rheum Dis Clin North Am* 2000; 26: 199–213, v.

19. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. *PLoS Med* 2006; 3: e491.

20. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 1992; 35: 630–640.

21. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009; 42: 377–381.

22. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf31-BLK and ITGAM-ITGAX. *N Engl J Med* 2008; 28(358): 900–909.

23. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. *Arthritis Rheum* 1999; 42: 338–346.

24. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. *Am J Epidemiol* 1997; 145: 408–415.

25. Eustace S, Hutchinson M and Bresnihan B. Acute cerebrovascular episodes in systemic lupus erythematosus. *Q J Med* 1991; 80: 739–750.

26. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. *Circulation* 2005; 112: 3337–3347.

27. Ross R. Atherosclerosis–an inflammatory disease. *N Engl J Med* 1999; 340: 115–126.

28. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum* 2001; 44: 2331–2337.

29. Lambers M, Goldberg NA, Kenet G, et al. Role of reduced ADAMTS13 in arterial ischemic stroke: a Pediatric Cohort Study. *Ann Neurol* 2013; 73: 58–64.

30. Moriguchi-Goto S, Yamashita A, Tamura N, et al. ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions. *Atherosclerosis* 2009; 203: 409–416.

31. Arning A, Hiersche M, Witten A, et al. A genome-wide association study identifies a gene network of ADAMTS genes in the predisposition to pediatric stroke. *Blood* 2012; 120: 5231–5236.
## Appendix 1

### Notation

| Acronym | Definition |
|---------|------------|
| ADAMTS13 | a disintegrin-like and metalloprotease with thrombospondin type 1 motif, member 13 |
| mRNA    | messenger RNA |
| SLE     | systemic lupus erythematosus |
| SLEDAI  | systemic Lupus Erythematosus Disease Activity Index |
| TIA     | transient ischemic attack |
| TTP     | thrombotic thrombocytopenic purpura |
| vWF     | von Willebrand factor |